No Data Available
Medicamen Biotech Share Price
Open | 458.00 |
High | 474.35 |
Low | 452.05 |
Prev Close | 458.40 |
Volume | 6,700 |
VWAP(₹) | 462.87 |
Medicamen Bio share price insights
Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 26.72% outperformed its 3 year CAGR of 16.79%. (Source: Consolidated Financials)Stock Returns vs Nifty Smallcap 100
Stock gave a 3 year return of -43.88% as compared to Nifty Smallcap 100 which gave a return of 48.97%. (as of last trading session)Employee & Interest Expense
Company has spent 2.45% of its operating revenues towards interest expenses and 16.77% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)Stock Returns vs Nifty Pharma
Stock generated -43.88% return as compared to Nifty Pharma which gave investors 62.52% return over 3 year time period. (as of last trading session)Medicamen Bio Share Price Update
Medicamen Biotech Ltd. share price moved up by 1.74% from its previous close of Rs 458.40. Medicamen Biotech Ltd. stock last traded price is 466.35
Share Price Value Today/Current/Last 466.35 Previous Day 458.40
Found Insights useful?
Medicamen Bio Share Price Returns
1 Day | 1.74% |
1 Month | -9.0% |
3 Months | -13.04% |
1 Year | -13.63% |
3 Years | -42.28% |
5 Years | N.A. |
Key Metrics
PE Ratio(x) | 83.68 |
EPS - TTM(₹) | 5.48 |
MCap(₹ Cr.) | 582.84 |
MCap Rank | 84 |
PB Ratio(x) | 2.83 |
Div Yield(%) | 0.22 |
Face Value(₹) | 10.00 |
52W High(₹) | 630.00 |
52W Low(₹) | 355.45 |
MCap/Sales | 2.72 |
Beta(1 Month) | - |
BV/Share(₹) | 162.79 |
Medicamen Bio Share Recommendations
No Recommendations details available for this stock.
Check out other stock recos.
Medicamen Bio News & Analysis
Medicamen Bio Financials
Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023 Total Income 45.03 43.63 47.89 47.33 44.09 Total Income Growth (%) 3.20 -8.88 1.17 7.35 4.18 Total Expenses 42.04 41.37 43.34 43.41 40.72 Total Expenses Growth (%) 1.60 -4.55 -0.16 6.62 11.01 EBIT 3.00 2.26 4.54 3.92 3.37 EBIT Growth (%) 32.51 -50.20 15.92 16.23 -40.22 Profit after Tax (PAT) 1.46 1.35 2.13 2.03 1.48 PAT Growth (%) 7.79 -36.50 4.82 37.46 -62.59 EBIT Margin (%) 6.66 5.18 9.49 8.28 7.65 Net Profit Margin (%) 3.23 3.10 4.44 4.29 3.35 Basic EPS (₹) 0.71 0.63 1.61 1.60 1.17 All figures in Rs Cr, unless mentioned otherwise
InsightsBeating 3 Yr Revenue CAGR
Company's annual revenue growth of 26.72% outperformed its 3 year CAGR of 16.79%. (Source: Consolidated Financials)Employee & Interest Expense
Company has spent 2.45% of its operating revenues towards interest expenses and 16.77% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Total Assets 294.55 278.52 225.69 194.01 181.28 Total Assets Growth (%) 5.76 23.41 16.33 7.02 32.72 Total Liabilities 87.57 85.10 79.22 61.12 60.07 Total Liabilities Growth (%) 2.89 7.42 29.63 1.75 20.23 Total Equity 206.98 193.41 146.47 132.89 121.22 Total Equity Growth (%) 7.02 32.05 10.22 9.63 39.92 Current Ratio (x) 1.89 1.98 1.69 1.80 1.84 Total Debt to Equity (x) 0.15 0.13 0.17 0.13 0.08 Contingent Liabilities - - - - - All figures in Rs Cr, unless mentioned otherwise
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Net Cash flow from Operating Activities -6.74 -6.29 4.11 12.77 12.80 Net Cash used in Investing Activities -5.56 -5.88 -8.47 -17.81 -37.29 Net Cash flow from Financing Activities 6.31 29.13 4.30 5.84 19.06 Net Cash Flow -5.99 16.95 -0.07 0.80 -5.43 Closing Cash & Cash Equivalent 14.79 20.78 3.82 3.89 3.09 Closing Cash & Cash Equivalent Growth (%) -28.84 443.27 -1.69 25.80 -63.70 Total Debt/ CFO (x) -4.57 -3.84 5.93 1.36 0.78 All figures in Rs Cr, unless mentioned otherwise
InsightsDecrease in Cash from Investing
Company has used Rs 5.56 cr for investing activities which is an YoY decrease of 5.4%. (Source: Consolidated Financials)
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Return on Equity (%) 5.28 7.77 10.17 9.12 10.96 Return on Capital Employed (%) 8.32 10.19 12.74 12.40 14.86 Return on Assets (%) 3.71 5.32 6.60 6.25 7.33 Interest Coverage Ratio (x) 5.59 9.01 18.04 16.41 32.63 Asset Turnover Ratio (x) 0.63 0.56 0.55 58.09 69.23 Price to Earnings (x) 44.64 56.18 52.91 54.05 16.61 Price to Book (x) 2.35 4.35 5.37 4.91 1.82 EV/EBITDA (x) 20.48 31.62 31.94 33.33 10.82 EBITDA Margin (%) 13.70 18.69 21.88 17.72 16.77
Found Financials useful?
Medicamen Bio Technicals
No Data Available
R1 - Pivot -
S1 - R2 - S2 - R3 - S3 - 5 Days 14 Days 28 Days - - -
Medicamen Bio Peer Comparison
- 1D
- 1W
- 1M
- 3M
- 6M
- 1Y
- 5Y
Choose from Peers
Choose from Stocks
Stock Returns vs Nifty Smallcap 100
Stock gave a 3 year return of -43.88% as compared to Nifty Smallcap 100 which gave a return of 48.97%. (as of last trading session)Stock Returns vs Nifty Pharma
Stock generated -43.88% return as compared to Nifty Pharma which gave investors 62.52% return over 3 year time period. (as of last trading session)
Mutual Funds Ownership
No Data Available
Medicamen Bio Top Searches
Corporate Actions
Board Meeting
Quarterly Results
Nov 07, 2024
General Meeting
Rs.1.0000 per share(10%)Final Dividend & A.G.M.
Aug 16, 2024
Board Meeting
Quarterly Results
Aug 07, 2024
Announced on Meeting on Nov 07, 2024 Nov 14, 2024 Quarterly Results Aug 07, 2024 Aug 13, 2024 Quarterly Results May 21, 2024 May 29, 2024 Audited Results & Final Dividend Feb 05, 2024 Feb 12, 2024 Quarterly Results Nov 02, 2023 Nov 10, 2023 Quarterly Results Announced on Ex-Date Dividend% May 29, 2024 Sep 19, 2024 10% Aug 11, 2023 Sep 20, 2023 10% May 25, 2022 Sep 19, 2022 10% Jun 28, 2021 Sep 16, 2021 10% Jun 30, 2020 Sep 17, 2020 5% No Data Available
No Data Available
No Data Available
Announced on Meeting on Aug 16, 2024 Sep 25, 2024 Rs.1.0000 per share(10%)Final Dividend & A.G.M. Aug 11, 2023 Sep 27, 2023 Rs.1.0000 per share(10%)Final Dividend & A.G.M. Sep 11, 2020 Sep 25, 2020 Book closure from Sep 19, 2020 to Sep 25, 2020 Sep 03, 2019 Sep 25, 2019 - Apr 15, 2019 May 06, 2019 -
About Medicamen Bio
Medicamen Biotech Ltd., incorporated in the year 1993, is a Small Cap company (having a market cap of Rs 592.95 Crore) operating in Pharmaceuticals sector.
Industry
Key Indices Listed On
BSE AllCap
Address
1506, Chiranjiv Tower,43, Nehru Place,New Delhi, Delhi - 110019
Executive Leadership
Rahul Bishnoi
ChairmanRajesh Madan
Chief Executive OfficerAshwani Kumar Sharma
Non Executive DirectorSanjay Bansal
Non Executive DirectorAuditors
FAQs about Medicamen Bio share
- 1. What's the Medicamen Bio share price today?As of today Medicamen Bio share price is up by 1.74% basis the previous closing price of Rs 453.15. Medicamen Bio share price was Rs 466.35. Return Performance of Medicamen Bio Shares:
- 1 Week: Medicamen Bio share price moved down by 0.48%
- 1 Month: Medicamen Bio share price moved down by 9.00%
- 3 Month: Medicamen Bio share price moved down by 13.04%
- 6 Month: Medicamen Bio share price moved up by 7.45%
- 2. What are the Medicamen Bio quarterly results?Total Revenue and Earning for Medicamen Bio for the year ending 2024-03-31 was Rs 181.63 Cr and Rs 10.93 Cr on Consolidated basis. Last Quarter 2024-09-30, Medicamen Bio reported an income of Rs 45.03 Cr and profit of Rs 1.46 Cr.
- 3. Who are the key owners of Medicamen Bio stock?Following are the key changes to Medicamen Bio shareholding:
- Promoter holding have gone down from 43.21 (31 Mar 2024) to 42.99 (31 Dec 2024)
- Domestic Institutional Investors holding have gone down from 0.99 (31 Mar 2024) to 0.87 (31 Dec 2024)
- Foreign Institutional Investors holding have gone down from 0.12 (31 Mar 2024) to 0.06 (31 Dec 2024)
- Other investor holding has gone up from 55.68 (31 Mar 2024) to 56.08 (31 Dec 2024)
- 4. What is the PE & PB ratio of Medicamen Bio?The PE ratio of Medicamen Bio stands at 84.17, while the PB ratio is 2.92.
- 5. What is the CAGR of Medicamen Bio?The CAGR of Medicamen Bio is 12.31.
- 6. What are the returns for Medicamen Bio share?Return Performance of Medicamen Bio Shares:
- 1 Week: Medicamen Bio share price moved down by 0.48%
- 1 Month: Medicamen Bio share price moved down by 9.00%
- 3 Month: Medicamen Bio share price moved down by 13.04%
- 6 Month: Medicamen Bio share price moved up by 7.45%
- 7. Who is the CEO of Medicamen Bio?Rajesh Madan is the Chief Executive Officer of Medicamen Bio
- 8. What is the market cap of Medicamen Bio?Medicamen Bio share has a market capitalization of Rs 582.84 Cr. Within Pharmaceuticals sector, it's market cap rank is 84.
- 9. What is 52 week high/low of Medicamen Bio share price?Medicamen Bio share price saw a 52 week high of Rs 630.00 and 52 week low of Rs 355.45.
- 10. Who's the chairman of Medicamen Bio?Rahul Bishnoi is the Chairman of Medicamen Bio
- 11. What dividend is Medicamen Bio giving?An equity Final dividend of Rs 1 per share was declared by Medicamen Biotech Ltd. on 29 May 2024. So, company has declared a dividend of 10% on face value of Rs 10 per share. The ex dividend date was 19 Sep 2024.
- 12. How can I quickly analyze Medicamen Bio stock?Key Metrics for Medicamen Bio are:
- PE Ratio of Medicamen Bio is 83.68
- Price/Sales ratio of Medicamen Bio is 2.72
- Price to Book ratio of Medicamen Bio is 2.83
- 13. Who are the peers for Medicamen Bio in Pharmaceuticals sector?Top 10 Peers for Medicamen Bio are Kilitch Drugs(I) Ltd., Zim Laboratories Ltd., Lyka Labs Ltd., SMS Lifesciences India Ltd., Venus Remedies Ltd., Brooks Laboratories Ltd., Wanbury Ltd., Medico Remedies Ltd., Ind-Swift Laboratories Ltd. and Albert David Ltd.
Top Gainers
As on 03:59 PM | 01 Feb 2025Top Losers
As on 03:59 PM | 01 Feb 2025Trending in Markets
DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).
DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.
By using this site, you agree to the Terms of Service and Privacy Policy.